检验医学与临床Issue(19)：2823-2826,4.DOI:10.3969/j.issn.1672-9455.2015.19.005
DC-CIK 联合化疗治疗中晚期食管鳞癌的临床疗效评价
Evaluation on clinical efficacy of DC-CIK combined with hemotherapy in treating moderate and advanced esophageal car-cinoma
摘要
Abstract
Objective To investigate the clinical efficacy of dentritic cells cytokines induced killer cell (DC‐CIK) combined with the chemotherapy of cisplatin plus docetaxel(DC regimen) in treating moderate and advanced e‐sophageal squamous carcinoma .Methods 100 patients with moderate and advanced esophageal squamous carcinoma were randomly divided into the treatment group and the control group ,50 cases in each group .The two groups were treated with the DC regimen .On the basis of chemotherapy ,the treatment group was given the DC‐CIK immune cell therapy .The short‐term effect after treatment ,adverse reactions ,peripheral serum concentrations of tumor markers before and after treatment and immune function were observed in the two groups .Results The short‐term and long‐term clinical efficacies after treatment in the treatment group were significantly better than those in the control group (P< 0 .05) ;the peripheral serum cyfra211 ,SCC ,CEA and CA125 levels after treatment in the two groups were de‐creased compared with before treatment ( P < 0 .05) ;after treatment ,the peripheral serum CD3 ,CD8 ,CD56/CD3 , CD16/CD3 ,IgG ,IgM and IgA in the treatment group were increased compared with before treatment (P < 0 .05) , while CD4/CD8 was decreased compared with that before treatment(P< 0 .05) ,CD4 had no significant change com‐pared with before treatment(P> 0 .05) .The peripheral serum CD3 ,CD8 ,CD4 ,CD4/CD8 ,CD56/CD3 and CD16/CD3 after treatment had no obvious changes compared with before treatment(P> 0 .05) ,while the IgG ,IgM and IgA lev‐els after treatment were decreased compared with before treatment(P< 0 .05) .The peripheral serum cyfra211 ,SCC , CEA and CA125 concentrations after treatment were lower than those in the control group(P< 0 .05) ;peripheral ser‐um CD3 ,CD8 ,CD56/CD3 ,CD16/CD3 ,IgG ,IgM and IgA levels after treatment in the treatment group were signifi‐cantly higher those in the control group(P< 0 .05) ,while CD4/CD8 was significantly lower than that in the control group(P< 0 .05) ,CD4 had no significant difference compared with the control group .Fever and chills occurred during therapy in the treatment group ;the two groups appeared different degrees of gastrointestinal reactions ,bone marrow suppression after treatment ,moreover the occurrence rates in the treatment group was lower than that in the control group(P< 0 .05) .Conclusion The DC‐CIK combined with chemotherapy can raise the clinical efficacy in treating moderate and advanced esophageal squamous carcinoma with less adverse reactions .关键词
中晚期食管鳞癌/DC-CIK/临床疗效/肿瘤标记物/免疫功能Key words
advanced esophageal carcinoma/DC-CIK/Clinical efficacy/tumor markers/immune func-tion引用本文复制引用
赵媛,宁实,杨光,张曙光..DC-CIK 联合化疗治疗中晚期食管鳞癌的临床疗效评价[J].检验医学与临床,2015,(19):2823-2826,4.基金项目
国家自然科学青年科学基金资助项目（81201890）；辽宁省自然科学基金资助项目（2013021002）。 （）
